Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HMN010
MIFTS: 60

Hemangioma

Categories: Blood diseases, Cancer diseases, Cardiovascular diseases, Fetal diseases, Rare diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Variations Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Hemangioma

About this section

MalaCards integrated aliases for Hemangioma:

Name: Hemangioma 11 75 28 53 5 43 14 16 71
Hemangiomas 14

Classifications:

MalaCards categories:
Global: Cancer diseases Fetal diseases Rare diseases
Anatomical: Cardiovascular diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 31


External Ids:

Disease Ontology 11 DOID:255
ICD9CM 34 228.00
MeSH 43 D006391
NCIt 49 C3085
SNOMED-CT 68 154625006
ICD10 31 D18.0
UMLS 71 C0018916
Sources

Summaries for Hemangioma

About this section

Disease Ontology: 11 A cardiovascular organ benign neoplasm that has material basis in endothelial cells that line blood vessels and is characterised by increased number of normal or abnormal vessels filled with blood.

MalaCards based summary: Hemangioma, also known as hemangiomas, is related to cavernous hemangioma and hemangioma, capillary infantile. An important gene associated with Hemangioma is PTEN (Phosphatase And Tensin Homolog), and among its related pathways/superpathways are Disease and CREB Pathway. The drugs Captopril and Ethiodized oil have been mentioned in the context of this disorder. Affiliated tissues include Heart, endothelial and skin, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia: 75 A hemangioma or haemangioma is a usually benign vascular tumor derived from blood vessel cell types. The... more...
Sources

Related Diseases for Hemangioma

About this section

Diseases in the Hemangioma family:

Malignant Hemangioma Acquired Hemangioma
Congenital Hemangioma

Diseases related to Hemangioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1574)
# Related Disease Score Top Affiliating Genes
1 cavernous hemangioma 33.2 VEGFA SLC2A1 PECAM1 KRIT1 KDR CD34
2 hemangioma, capillary infantile 33.2 KDR FLT4 ANTXR1
3 capillary hemangioma 33.1 VEGFA TEK SLC2A1 PROX1 PECAM1 KDR
4 cerebral cavernous malformations 33.1 PTEN PROX1 PECAM1 KRIT1 KDR
5 rapidly involuting congenital hemangioma 32.9 SLC2A1 PECAM1 FLT4
6 spindle cell hemangioma 32.8 PROX1 PECAM1 CD34
7 glomeruloid hemangioma 32.8 VEGFA PECAM1 CD34
8 arteriovenous malformation 32.7 VEGFA TEK SLC2A1 PECAM1 MAP2K1 KRIT1
9 pyogenic granuloma 32.7 VEGFA TEK SLC2A1 PECAM1 FLT4 CD34
10 intramuscular hemangioma 32.6 TEK PECAM1 MAP2K1 CD34
11 skin epithelioid hemangioma 32.5 PECAM1 CD34
12 histiocytoid hemangioma 32.5 PECAM1 CD34
13 hemangioma of spleen 32.5 PECAM1 CD34
14 central nervous system hemangioma 32.5 VEGFA PECAM1 CD34
15 venous hemangioma 32.4 PECAM1 CD34
16 hobnail hemangioma 32.4 PECAM1 PDPN FLT4 CD34
17 breast hemangioma 32.4 PECAM1 CD34
18 epithelioid hemangioendothelioma 32.3 PECAM1 FLT4 CD34
19 hemangioendothelioma 32.3 FLT4 CD34
20 acquired hemangioma 32.3 VEGFA PROX1 PECAM1 PDPN CD34
21 chorioangioma 32.2 PECAM1 CD34
22 liver angiosarcoma 32.1 PECAM1 KRAS CD34
23 senile angioma 32.1 MAP2K1 KDR
24 vascular cancer 31.9 VEGFA PECAM1 KDR FLT4 FGF2 CD34
25 angiosarcoma 31.5 VEGFA TEK PECAM1 PDPN KRAS KDR
26 meningioma, familial 31.3 VEGFA SLC2A1 PTEN PECAM1 PDPN CD34
27 lymphangioma 31.3 VEGFA PROX1 PECAM1 PDPN KRAS KDR
28 kaposi sarcoma 31.2 VEGFA PECAM1 PDPN KDR FLT4 FGF2
29 klippel-trenaunay-weber syndrome 31.2 VEGFA TEK PTEN PROX1 PECAM1 KRIT1
30 vascular disease 31.1 VEGFA TEK KRIT1 KDR FGF2
31 pericardial effusion 31.1 VEGFA FGF2 CD34
32 lipomatosis, multiple 31.0 PTEN PECAM1 CD34
33 retinal vascular disease 31.0 VEGFA TEK KDR FGF2
34 intussusception 31.0 VEGFA TEK PECAM1 KDR FGF2 CD34
35 renal cell carcinoma, nonpapillary 30.9 VEGFA TEK SLC2A1 PTEN PECAM1 PDPN
36 hemangioblastoma 30.9 VEGFA SLC2A1 PECAM1 PDPN CD34
37 microvascular complications of diabetes 5 30.8 VEGFA TEK SLC2A1 KDR FGF2
38 adenocarcinoma 30.8 VEGFA PTEN NKX2-1 MAP2K1 KRAS KDR
39 melanoma 30.8 VEGFA PTEN PECAM1 PDPN MAP2K1 KRAS
40 wilms tumor 1 30.8 VEGFA PTEN PECAM1 NKX2-1 KRAS CD34
41 macular degeneration, age-related, 1 30.7 VEGFA TEK PECAM1 KDR FGF2
42 angiolipoma 30.7 PECAM1 CD34
43 cystic lymphangioma 30.7 PROX1 PECAM1 PDPN FLT4 CD34
44 neovascular glaucoma 30.7 VEGFA KDR FGF2
45 lung cancer susceptibility 3 30.7 VEGFA PECAM1 NKX2-1 MAP2K1 KRAS KDR
46 neuroblastoma 30.6 VEGFA PTEN MAP2K1 KDR FGF2 CD34
47 hereditary lymphedema i 30.6 PROX1 PDPN FLT4
48 exudative vitreoretinopathy 1 30.6 VEGFA TEK PECAM1 KDR FLT4 FGF2
49 rhabdomyosarcoma 30.6 VEGFA PTEN MAP2K1 KRAS KDR FGF2
50 neurofibroma 30.6 VEGFA PTEN PDPN CD34

Graphical network of the top 20 diseases related to Hemangioma:



Diseases related to Hemangioma
Sources

Symptoms & Phenotypes for Hemangioma

About this section

MGI Mouse Phenotypes related to Hemangioma:

45 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.45 CD34 DIO3 DIPK1A FGF2 FLT4 KDR
2 growth/size/body region MP:0005378 10.44 ANTXR1 DIO3 DIPK1A FLT4 KDR KRAS
3 nervous system MP:0003631 10.34 FGF2 KDR KRAS KRIT1 MAP2K1 NKX2-1
4 muscle MP:0005369 10.33 FGF2 FLT4 KDR KRAS KRIT1 PDPN
5 cardiovascular system MP:0005385 10.33 ANTXR1 DIPK1A FGF2 FLT4 KDR KRAS
6 neoplasm MP:0002006 10.28 ANTXR1 CD34 FGF2 KRAS KRIT1 MAP2K1
7 cellular MP:0005384 10.28 ANTXR1 CD34 DIO3 FGF2 KDR KRAS
8 normal MP:0002873 10.27 FLT4 KDR KRAS MAP2K1 NKX2-1 PKD1
9 liver/biliary system MP:0005370 10.24 DIO3 FLT4 KDR KRAS PECAM1 PKD1
10 embryo MP:0005380 10.24 FLT4 KDR KRAS KRIT1 MAP2K1 PKD1
11 digestive/alimentary MP:0005381 10.18 FLT4 KRAS MAP2K1 NKX2-1 PDPN PECAM1
12 no phenotypic analysis MP:0003012 10.11 ANTXR1 FLT4 KDR KRAS NKX2-1 SLC2A1
13 craniofacial MP:0005382 10.06 ANTXR1 KDR KRAS KRIT1 MAP2K1 PKD1
14 skeleton MP:0005390 10.03 ANTXR1 FGF2 KDR KRAS MAP2K1 NKX2-1
15 respiratory system MP:0005388 10.02 KDR KRAS NKX2-1 PDPN PECAM1 PKD1
16 reproductive system MP:0005389 10.02 ANTXR1 DIO3 FGF2 FLT4 KRAS MAP2K1
17 hematopoietic system MP:0005397 9.93 CD34 FGF2 KDR KRAS PDPN PECAM1
18 mortality/aging MP:0010768 9.89 ANTXR1 DIO3 FGF2 FLT4 KDR KRAS
19 integument MP:0010771 9.4 CD34 FLT4 KDR KRAS KRIT1 MAP2K1
Sources

Drugs & Therapeutics for Hemangioma

About this section

Drugs for Hemangioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 191)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Captopril Approved Phase 4 62571-86-2 44093
2
Ethiodized oil Approved, Investigational Phase 4 8008-53-5
3
Parecoxib Approved Phase 4 198470-84-7 119828
4
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
5
Timolol Approved Phase 4 26839-75-8 5478 33624
6
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643
7
Atenolol Approved Phase 4 29122-68-7 2249
8
Medroxyprogesterone acetate Approved, Investigational Phase 4 520-85-4, 71-58-9 6279 10631
9
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
10 Angiotensin-Converting Enzyme Inhibitors Phase 4
11 HIV Protease Inhibitors Phase 4
12
protease inhibitors Phase 4
13 Antirheumatic Agents Phase 4
14 Dsuvia Phase 4
15 Cyclooxygenase Inhibitors Phase 4
16 Cyclooxygenase 2 Inhibitors Phase 4
17 Anti-Inflammatory Agents, Non-Steroidal Phase 4
18 Analgesics, Non-Narcotic Phase 4
19 Pharmaceutical Solutions Phase 4
20 Ophthalmic Solutions Phase 4
21 Anesthetics Phase 4
22 Calcineurin Inhibitors Phase 4
23 Adrenergic beta-1 Receptor Antagonists Phase 4
24 Sympatholytics Phase 4
25 Liver Extracts Phase 4
26 Antineoplastic Agents, Hormonal Phase 4
27 Contraceptives, Oral, Hormonal Phase 4
28 Contraceptives, Oral Phase 4
29 Contraceptive Agents, Male Phase 4
30 Contraceptive Agents Phase 4
31
Nadolol Approved Phase 3 42200-33-9 39147
32
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
33
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
34
Prednisolone Approved, Vet_approved Phase 3 50-24-8 4894 5755
35
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5 1875
36
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 4159 6741
37
Acebutolol Approved, Investigational Phase 3 37517-30-9 1978
38
Maleic acid Experimental, Investigational Phase 3 110-16-7, 110-17-8 444266 444972
39
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7 4897
40 Adrenergic beta-Antagonists Phase 3
41 Adrenergic Antagonists Phase 3
42 Neurotransmitter Agents Phase 3
43 Adrenergic Agents Phase 3
44 Anti-Arrhythmia Agents Phase 3
45 Antihypertensive Agents Phase 3
46 Hormones Phase 3
47 Hormone Antagonists Phase 3
48 glucocorticoids Phase 3
49 Anti-Inflammatory Agents Phase 3
50
Methylprednisolone Acetate Phase 3 584547

Interventional clinical trials:

(show top 50) (show all 191)
# Name Status NCT ID Phase Drugs
1 Evaluation of the Efficacy of Captopril Versus Propranolol and Timolol as a Treatment of Infantile Capillary Hemangioma Unknown status NCT04288700 Phase 4 oral propranolol;Oral Captopril;intralesional propranolol injection;topical Timolol maleate 0.5% eye drops
2 Safety and Efficacy of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization. A Phase IV Study. Unknown status NCT02625389 Phase 4 Lipiodol® Ultra Fluid with surgical glues
3 A Randomized, Phase IV Study Exploring the Role of Parecoxib Sodium for Postoperative Pain Management in Open Hepatectomy Unknown status NCT02204878 Phase 4 Parecoxib Sodium
4 The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma Completed NCT01908972 Phase 4 Prednisolone;Propranolol
5 A Pilot Study of Hemoporfin Photodynamic Therapy in Children (7-14 Years Old) With Port-wine Stain Completed NCT03125057 Phase 4 Hemoporfin PDT
6 DOUBLE-SKIN: a New Approach in Laser Surgery Using the Regenerative Solution in Children Diagnosed With Vascular Pathology: a Randomised, Double-blind, Placebo-controlled Trial Completed NCT04999618 Phase 4 Haemoblock
7 Assessing the Impact of Dosage Frequency of Propranolol on Sleep Patterns in Patients With Infantile Hemangiomas Recruiting NCT05479123 Phase 4 Propranolol three times a day;Propranolol twice a day;Timolol
8 Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma:A Prospective, Randomized Open Trial Recruiting NCT04077515 Phase 4 Sirolimus(0.8mg/m2);Sirolimus(0.7mg/m2)
9 A Pilot Study of Hemoporfin Photodynamic Therapy in Children (2-7 Years Old) With Port-wine Stain Recruiting NCT04106258 Phase 4 Hemoporfin PDT
10 Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma: a Single Arm Prospective Study Recruiting NCT04056962 Phase 4 Tacrolimus ointment
11 Postmarketing Safety Study of Hemoporfin in Patients With Port Wine Stain Active, not recruiting NCT03181984 Phase 4 Hemoporfin
12 The Efficacy and Safety of Beta-blockers Drugs in Adults With Spinal Hemangioma: a Prospective Cohort Study Enrolling by invitation NCT05106179 Phase 4 Atenolol Pill;Propranolol Pill
13 Management of Uterine Arteriovenous Malformation- a Comparison of 2 Management Possibilities- Observation vs. Progesterone Treatment/ a Randomized Control Trial Not yet recruiting NCT05491343 Phase 4 MedroxyPROGESTERone Injection [Depo-Provera]
14 Comparative Study to Evaluate the Effectiveness of Atenolol and Propranolol in the Treatment of Infantile Hemangiomas Unknown status NCT03237637 Phase 3 oral propranolol;oral atenolol
15 Treatment of Cutaneous Hemangioma of Infancy With Topical 0.5% Timolol Maleate Eye Drop Compared With Placebo in Pediatric Patients, Siriraj Hospital Unknown status NCT01685398 Phase 3 0.5% timolol maleate eye drop;Normal saline
16 CyberKnife Based Hypofractionated Radiotherapy Versus Conventional Linac Based Radiotherapy for Painful Vertebral Hemangiomas - Controlled Randomized Clinical Trial. Unknown status NCT02332408 Phase 3
17 Blood Oxygen Level Dependent fMRI Navigation for Function Protection in Intracranial Arteriovenous Malformation Surgery: a Multicenter Prospective Randomized Controlled Single Blind Clinical Trial Unknown status NCT01758211 Phase 3
18 Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel Unknown status NCT01272609 Phase 3 Timolol + LCP
19 Nadolol Versus Propranolol in Children With Infantile Hemangiomas: a Randomized, Controlled, Double-blinded Trial Completed NCT02505971 Phase 3 Nadolol;Propranolol
20 Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma Completed NCT02342275 Phase 3 Propranolol;Atenolol
21 A Randomised, Controlled, Multidose, Multicentre, Adaptive Phase II/III Study in Infants With Proliferating Infantile Hemangiomas (IHs) Requiring Systemic Therapy to Compare 4 Regimens of Propranolol (1 or 3 mg/kg/Day for 3 or 6 Months) to Placebo (Double Blind). Completed NCT01056341 Phase 2, Phase 3 Propranolol;Placebo
22 A Randomized Trial of Unruptured Brain Arteriovenous Malformations Completed NCT00389181 Phase 3
23 A Multicenter, Open-label Study for E7040 in Japanese Subjects With Hypervascular Tumor and Subjects With Arteriovenous Malformation Completed NCT01677624 Phase 3
24 The Efficacy and Safety of Intravenous Pulse Steroids Compared to Standard Oral Steroids in the Treatment of Problematic Hemangiomas in Infants: A Randomized Controlled Trial Completed NCT00312520 Phase 3 prednisolone;methylprednisolone
25 Double Blind, Randomised, Placebo-controlled Study of Propranolol in Infantile Capillary Hemangiomas Terminated NCT00744185 Phase 2, Phase 3 propranolol treatment;placebo treatment
26 Efficacy and Safety of Propranolol Versus Acebutolol on the Proliferative Phase of Infantile Hemangioma Terminated NCT01743885 Phase 3 Acebutolol;Propanolol
27 '' Efficacy of Propranolol in the Treatment of Infantile Hemangioma" Unknown status NCT04684667 Phase 2 Propranolol Therapy for Infantile Hemangioma
28 Effect of Oral Propranolol on mRNA Expression in Symptomatice Caavernous Malformation Unknown status NCT03474614 Phase 2 Propranolol
29 Topical Timolol Gel for the Treatment of Infantile Hemangiomas Completed NCT02145884 Phase 2 timolol maleate 0.5% gel
30 Efficacy and Safety of Topical Timolol Maleate 0.5% Solution for Superficial Infantile Hemangioma in Early Proliferative Phase. A Randomized Clinical Trial Completed NCT02731287 Phase 2 Timolol;Placebo
31 A Phase II Study of Imiquimod 5 % Cream for the Treatment of Hemangioma in Infancy Completed NCT00601016 Phase 2 Imiquimod 5% cream
32 Nadolol for Proliferating Infantile Hemangiomas: A Prospective Open Label Study With a Historical Control Completed NCT01010308 Phase 2 Nadolol
33 A Comparative Study of the Use of Beta Blocker and Oral Corticosteroid in the Treatment of Proliferative and Involuting Cutaneous Infantile Hemangioma Completed NCT01072045 Phase 2 Propranolol;Prednisone
34 Efficacy, Safety, and Pharmacokinetics of Timolol in Infants With Infantile Hemangioma (IH) Completed NCT02913612 Phase 2 0.25% Timolol Maleate Gel Forming Solution;0.5% Timolol Maleate Gel Forming Solution
35 A Randomised, Double Blind, Controlled, Multicentre Study in Infants With Infantile Hemangioma to Compare Propranolol Gel to Placebo. Completed NCT01512173 Phase 2 propranolol gel;Placebo
36 U.S. Multicenter, Randomized Controlled Study Comparing the Performance fo Onyx(EVOH) and TRUFILL® (n-BCA)in Presurgical Embolization of Brain Arteriovenous Malformations (BAVMs) Completed NCT00857662 Phase 2
37 Phase II Clinical Trial is to Compare Epidermal Temperature Measurements During 1.Laser Treatment at Standard Treatment Energies 2.Cryogen Spray Cooling (CSC) Plus Laser Treatment. 3.Contact Cooling Plus Laser Treatment. Completed NCT00540917 Phase 2
38 Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding Completed NCT00389935 Phase 2 Thalidomide
39 Treat_CCM Clinical Trial A Multicenter Randomized Clinical Trial on Propranolol in Familial Cerebral Cavernous Malformation Completed NCT03589014 Phase 2 Propranolol
40 Treatment of Port-wine Stains by Bosentan in Addition to Pulsed Dye Laser (PDL) in Children or Young Adults Who Previously Failed to Respond to PDL Alone: a Monocentric Pilot Study Completed NCT02317679 Phase 2 Bosentan
41 Efficacy Evaluation of Propranolol Treatment of Hepatic Hemangioma Recruiting NCT03633747 Phase 1, Phase 2 Propranolol Hydrochloride
42 Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations Recruiting NCT02042326 Phase 2 Sirolimus
43 COBI-AVM Study - Phase 2 Study to Assess the Safety and Efficacy of Cobimetinib In Extracranial Arteriovenous Malformations (AVM) Recruiting NCT05125471 Phase 2 Cobimetinib
44 A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of REC-994 in the Treatment of Symptomatic Cerebral Cavernous Malformation Recruiting NCT05085561 Phase 2 REC-994;Placebo
45 Phase I-II Randomized, Placebo-Controlled, Single-Blinded, Single-Site Clinical Trial of Atorvastatin in the Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Active, not recruiting NCT02603328 Phase 1, Phase 2 Atorvastatin
46 Lovastatin for Treatment of Brain Arteriovenous Malformations:a Double-blind, Placebo-controlled Randomized Trial Not yet recruiting NCT04297033 Phase 2 Lovastatin;Placebo
47 A Multi-Center, Randomized Study to Evaluate the Efficacy and Safety of Light Dose (Fluence) in Subjects With Port Wine Stain Treated With Hemoporfin + Green Light Photodynamic Therapy Not yet recruiting NCT05171894 Phase 2 Hemopfin+PDF;Vehicle+PDF
48 A Phase II, Randomized, Double-Blind Comparison of Corticosteroid and Corticosteroids With Propranolol Treatment of Infantile Hemangiomas (IH) Terminated NCT01074437 Phase 2 Prednisolone (Corticosteroid);Propranolol;Placebo
49 A Phase II, Randomized, Clinical Trial Assessing Efficacy And Safety Of Oral Prednisolone vs Intravenous Vincristine In The Treatment Of Infantile Terminated NCT00555464 Phase 2 Vincristine;Prednisone
50 Propranolol vs Prednisolone for Infant Hemangiomas-A Clinical and Molecular Study Terminated NCT00967226 Phase 2 propranolol;Prednisolone

Search NIH Clinical Center for Hemangioma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b

Cochrane evidence based reviews: hemangioma

Sources

Genetic Tests for Hemangioma

About this section

Genetic tests related to Hemangioma:

# Genetic test Affiliating Genes
1 Hemangioma 28
Sources

Anatomical Context for Hemangioma

About this section

Organs/tissues related to Hemangioma:

MalaCards : Endothelial, Skin, Liver, Brain, Eye, Spinal Cord, Heart
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Hemangioma:
# Tissue Anatomical CompartmentCell Relevance
1 Heart Cardinal Veins Venous Endothelial Cells Affected by disease
Sources

Publications for Hemangioma

About this section

Articles related to Hemangioma:

(show top 50) (show all 19979)
# Title Authors PMID Year
1
[Sinusoidal hemangioma: Immunohistochemical analysis with glucose transporter 1 (GLUT1) and williams tumor protein 1 (WT1)]. 53 62
20487697 2010
2
Differential expression of VEGF121, VEGF165 and VEGF189 in angiomas and squamous cell carcinoma cell lines of the head and neck. 53 62
20393000 2010
3
Corticosteroid suppression of VEGF-A in infantile hemangioma-derived stem cells. 53 62
20237346 2010
4
Local serum levels of vascular endothelial growth factor in infantile hemangioma: intriguing mechanism of endothelial growth. 53 62
20015661 2010
5
Facial nerve hemangiomas: vascular tumors or malformations? 53 62
20096233 2010
6
[Distribution, GLUT-1 expression and early surgical intervention for infantile hemangioma on the face]. 53 62
20030103 2009
7
Fulvene-5 potently inhibits NADPH oxidase 4 and blocks the growth of endothelial tumors in mice. 53 62
19620773 2009
8
Serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in children with hemangiomas and vascular malformations--preliminary report. 53 62
19689513 2009
9
Treatment of hemangioma by transfection of antisense VEGF gene. 53 62
19513617 2009
10
[POEMS syndrome with an isolated lytic lesion and glomeruloid hemangiomas: report of one case]. 53 62
19701559 2009
11
Identification of signaling systems in proliferating and involuting phase infantile hemangiomas by genome-wide transcriptional profiling. 53 62
19349369 2009
12
[Expression and significance of basic fibroblast growth factor in infant vascular anomalies]. 53 62
19417990 2009
13
A potential role for notch signaling in the pathogenesis and regulation of hemangiomas. 53 62
19169152 2009
14
Suppressing NFAT increases VEGF signaling in hemangiomas. 53 62
19061833 2008
15
Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. 53 62
18931684 2008
16
Solitary pulmonary infantile hemangioma in an infant with atrial septal defect. 53 62
17990917 2008
17
Incidental reduction in the size of liver hemangioma following use of VEGF inhibitor bevacizumab. 53 62
18814928 2008
18
GLUT-1 expression in mesenchymal tumors: an immunohistochemical study of 247 soft tissue and bone neoplasms. 53 62
18620729 2008
19
[Current treatment of infantile hemangiomas: an overview of the literature]. 53 62
18784870 2008
20
Possibilities and potential roles of estrogen in the pathogenesis of proliferation hemangiomas formation. 53 62
18434035 2008
21
Use of thalidomide to diminish growth velocity in a life-threatening congenital intracranial hemangioma. 53 62
18671617 2008
22
Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice. 53 62
18535669 2008
23
Treatment with interferon-alpha-2b in children with life-threatening hemangiomas. 53 62
18261103 2008
24
Podoplanin is a useful diagnostic marker for epithelioid hemangioendothelioma of the liver. 53 62
18084256 2008
25
Lack of expression of podoplanin by microvenular hemangioma. 53 62
18650031 2008
26
Proliferation hemangiomas formation through dual mechanism of vascular endothelial growth factor mediated endothelial progenitor cells proliferation and mobilization through matrix metalloproteinases 9. 53 62
17888584 2008
27
Eccrine angiomatous hamartoma with features resembling verrucous hemangioma. 53 62
17997743 2007
28
[Expression and significance of Ang1, Ang2 and receptor Tie2 in hemangioma]. 53 62
18269030 2007
29
Effect of anti-KDR antibody on the proliferation of hemangioma vascular endothelial cells in vitro. 53 62
18060633 2007
30
[Head and neck hemangiomas: how and when to treat]. 53 62
17924011 2007
31
[Iodothyronine deiodinases expression in thyroid neoplasias]. 53 62
17891232 2007
32
Placental anomalies in children with infantile hemangioma. 53 62
17845154 2007
33
[Differential expression of CD133, Glut-1 in tissues and endothelial cells derived from infantile hemangioma and vascular malformation]. 53 62
17926859 2007
34
[The expression and role of glucose transporter-1 in infantile hemangioma]. 53 62
17554865 2007
35
GLUT-1 in oral benign vascular lesions. 53 62
17241430 2007
36
[Expression of PCNA, VEGF and bFGF in endothelial cells of juvenile nasopharyngeal angiofibroma]. 53 62
17285972 2006
37
Pharmacologic blockade of angiopoietin-2 is efficacious against model hemangiomas in mice. 53 62
16741507 2006
38
Hemangiomas and homeobox gene expression. 53 62
16877932 2006
39
[Delayed disappearance of h-VEGF₁₆₅ mRNA and protein under regulation of hypoxic response element]. 53 62
16786114 2006
40
Vascular complications in Chuvash polycythemia. 53 62
16673284 2006
41
Infantile hemangioma is a proliferation of LYVE-1-negative blood endothelial cells without lymphatic competence. 53 62
16424896 2006
42
[Role of urinary basic fibroblast growth factor in differentiating hemangiomas from vascular malformation]. 53 62
16635349 2006
43
The potential efficacy of omega-3 fatty acids as anti-angiogenic agents in benign vascular tumors of infancy. 53 62
16500033 2006
44
Unique association of non-functioning pheochromocytoma, ganglioneuroma, adrenal cortical adenoma, hepatic and vertebral hemangiomas in a patient with a new intronic variant in the VHL gene. 53 62
16483185 2005
45
Transgenic rabbits with increased VEGF expression develop hemangiomas in the liver: a new model for Kasabach-Merritt syndrome. 53 62
16200077 2005
46
Transforming growth factor-beta promotes inactivation of extracellular thyroid hormones via transcriptional stimulation of type 3 iodothyronine deiodinase. 53 62
16037131 2005
47
Hemangiomas of infancy: clinical and biological characteristics. 53 62
16327961 2005
48
Assessment of angiogenic markers in oral hemangiomas and pyogenic granulomas. 53 62
16005715 2005
49
Expression patterns of markers for type II pneumocytes in pulmonary sclerosing hemangiomas and fetal lung tissues. 53 62
15974816 2005
50
Circulating level of vascular endothelial growth factor in differentiating hemangioma from vascular malformation patients. 53 62
15988268 2005
Sources

Variations for Hemangioma

About this section

ClinVar genetic disease variations for Hemangioma:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 PTEN NM_000314.8(PTEN):c.675T>G (p.Tyr225Ter) SNV Pathogenic
 404162 rs1057520900 GRCh37: 10:89717650-89717650
GRCh38: 10:87957893-87957893
2 DIPK1A, RPL5 NM_000969.5(RPL5):c.74-1G>C SNV Pathogenic
 523383 rs1553284997 GRCh37: 1:93299101-93299101
GRCh38: 1:92833544-92833544
3 PKD1 NM_001009944.3(PKD1):c.359T>C (p.Ile120Thr) SNV Likely Pathogenic
 523386 rs1555459345 GRCh37: 16:2169115-2169115
GRCh38: 16:2119114-2119114
4 overlap with 5 genes GRCh37/hg19 14q24.1(chr14:68126321-68269053)x3 CN GAIN Uncertain Significance
 635772 GRCh37: 14:68110557-68283783
GRCh38:
5 SRD5A3-AS1, SRD5A3 NM_024592.5(SRD5A3):c.951_955del (p.Phe318fs) DEL Uncertain Significance
 632442 rs565935886 GRCh37: 4:56236248-56236252
GRCh38: 4:55370081-55370085
6 NOTCH1 NM_017617.5(NOTCH1):c.5674G>A (p.Gly1892Arg) SNV Uncertain Significance
 983426 rs761427888 GRCh37: 9:139395264-139395264
GRCh38: 9:136500812-136500812
7 CSMD3 GRCh37/hg19 8q23.3(chr8:114378494-114450308) CN LOSS Benign
 523292 GRCh37: 8:114378494-114450308
GRCh38:
Sources

Expression for Hemangioma

About this section
Search GEO for disease gene expression data for Hemangioma.
Sources

Pathways for Hemangioma

About this section

Pathways related to Hemangioma according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Super pathways Score Top Affiliating Genes
1
Disease 66
Show member pathways
 13.79 VEGFA SLC2A1 RPL5 PTEN MAP2K1 KRAS
2
CREB Pathway 64
Show member pathways
 13.3 FGF2 FLT4 KDR KRAS MAP2K1 PTEN
3
PAK Pathway 64
Show member pathways
 13.27 TEK SLC2A1 PTEN KRAS KDR FLT4
4
Nanog in Mammalian ESC Pluripotency 64
Show member pathways
 13.25 FGF2 FLT4 KDR KRAS MAP2K1 TEK
5
Phospholipase-C Pathway 64
Show member pathways
 13.05 PTEN MAP2K1 KRAS KDR FLT4 FGF2
6
Signaling by Receptor Tyrosine Kinases 66
12.78 VEGFA MAP2K1 KRAS KDR FLT4 FGF2
7
Endometrial cancer 74
Show member pathways
 12.62 VEGFA PTEN MAP2K1 KRAS KDR FGF2
8
PI3K-Akt signaling pathway 74
Show member pathways
 12.62 VEGFA TEK SLC2A1 PTEN MAP2K1 KRAS
9
Overview of interferons-mediated signaling pathway 74
Show member pathways
 12.61 MAP2K1 KRAS KDR FLT4 FGF2
10
Malignant pleural mesothelioma 74
12.47 FGF2 FLT4 KDR MAP2K1 PTEN SLC2A1
11
NF-kappaB Pathway 70
Show member pathways
 12.41 FLT4 KDR KRAS MAP2K1
12
Breast cancer pathway 74
Show member pathways
 12.41 PTEN MAP2K1 KRAS FLT4 FGF2
13
VEGF Pathway (Qiagen) 64
Show member pathways
 12.4 VEGFA MAP2K1 KRAS KDR FLT4
14
RhoGDI Pathway 64
Show member pathways
 12.38 VEGFA KDR FLT4 FGF2
15
Development VEGF signaling via VEGFR2 - generic cascades 22
Show member pathways
 12.38 VEGFA MAP2K1 KRAS KDR
16
G-protein signaling RAC1 in cellular process 22
Show member pathways
 12.33 FGF2 FLT4 KDR KRAS MAP2K1 TEK
17
Signaling by VEGF 66
Show member pathways
 12.3 VEGFA KRAS KDR FLT4
18
Focal adhesion 74
12.26 VEGFA PTEN MAP2K1 KDR
19
Epithelial to mesenchymal transition in colorectal cancer 74
12.15 PROX1 PKD1 MAP2K1 KRAS
20
Ras signaling 74
12.14 FLT4 KDR KRAS MAP2K1 TEK
21
Tyrosine Kinases / Adaptors 3
12.11 TEK KDR FLT4 FGF2
22
CCR3 Pathway in Eosinophils 64
Show member pathways
 12.09 VEGFA MAP2K1 KRAS KDR
23
MAPK Signaling: Mitogens 65
Show member pathways
 12.07 TEK PTEN MAP2K1 KRAS KDR FLT4
24
mTOR Signaling 65
12.06 FLT4 KDR KRAS PTEN
25
Embryonic and Induced Pluripotent Stem Cells and Lineage-specific Markers 65
12.03 VEGFA PROX1 KDR FGF2
26
VEGF Signaling Pathway 60 67
Show member pathways
 12.03 VEGFA PTEN MAP2K1 KRAS KDR FGF2
27
CCL18 signaling pathway 74
11.87 VEGFA PTEN FGF2
28
Hippo-Merlin signaling dysregulation 74
Show member pathways
 11.84 TEK KDR FLT4
29
Clear cell renal cell carcinoma pathways 74
11.78 VEGFA SLC2A1 PTEN KDR
30
Neural Stem Cells and Lineage-specific Markers 65
11.77 VEGFA SLC2A1 FGF2
31
Head and neck squamous cell carcinoma 74
11.73 VEGFA PTEN KRAS
32
VEGF Pathway (Tocris) 70
Show member pathways
 11.71 MAP2K1 KRAS KDR FLT4
33
Signaling events mediated by VEGFR1 and VEGFR2 61
11.66 VEGFA MAP2K1 KDR
34
BDNF-TrkB signaling 74
Show member pathways
 11.63 PTEN MAP2K1 KRAS
35
Integrins in angiogenesis 61
11.6 VEGFA KDR FGF2
36
Cell adhesion_Plasmin signaling 22
11.51 VEGFA KDR FGF2
37
SHP2 signaling 61
11.49 VEGFA TEK MAP2K1 KDR
38
NRP1-triggered signaling pathways in pancreatic cancer 74
11.46 VEGFA PECAM1 MAP2K1 KDR
39
Bladder cancer 74
11.41 VEGFA MAP2K1 KRAS
40
Beta3 integrin cell surface interactions 61
11.39 VEGFA PECAM1 KDR
41
HIF-2-alpha transcription factor network 61
11.25 VEGFA SLC2A1 KDR
42
Aryl hydrocarbon receptor pathway 74
11.24 VEGFA MAP2K1 KRAS
43
Angiogenesis (CST) 3
11.12 TEK PROX1 PECAM1 PDPN KDR FLT4
44
Vemurafenib Pathway, Pharmacodynamics 60
11.07 VEGFA MAP2K1 KRAS KDR FLT4 FGF2
45
VEGFR2 mediated cell proliferation 66
11.06 VEGFA KRAS KDR
46
G-protein signaling_Rap2B regulation pathway 22
11 TEK MAP2K1 KDR FLT4 FGF2
47
Angiogenesis (WikiPathways) 74
10.99 TEK KDR FGF2
48
VEGF ligand-receptor interactions 66
Show member pathways
 10.87 VEGFA KDR FLT4
49
S1P1 pathway 61
10.86 VEGFA KDR
50
Regorafenib Pathway, Pharmacodynamics 60
10.45 TEK KDR FLT4
Sources

GO Terms for Hemangioma

About this section

Cellular components related to Hemangioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 anchoring junction GO:0070161 9.7 TEK PECAM1 PDPN KRIT1 KDR
2 plasma membrane GO:0005886 9.7 TEK SLC2A1 PKD1 PECAM1 PDPN KDR
3 plasma membrane GO:0005887 9.7 TEK SLC2A1 PKD1 PECAM1 PDPN KDR
4 membrane raft GO:0045121 9.61 TEK SLC2A1 PECAM1 PDPN KDR

Biological processes related to Hemangioma according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 10.45 VEGFA TEK PTEN PDPN KDR FLT4
2 positive regulation of cell population proliferation GO:0008284 10.4 FGF2 FLT4 KDR KRAS PROX1 PTEN
3 positive regulation of gene expression GO:0010628 10.38 VEGFA RPL5 NKX2-1 MAP2K1 KRAS FGF2
4 positive regulation of cell migration GO:0030335 10.35 VEGFA PECAM1 PDPN KDR FLT4
5 peptidyl-tyrosine phosphorylation GO:0018108 10.28 TEK MAP2K1 KDR FLT4
6 positive regulation of angiogenesis GO:0045766 10.21 CD34 FGF2 KDR TEK VEGFA
7 angiogenesis GO:0001525 10.18 VEGFA TEK PTEN KRIT1 KDR FLT4
8 protein kinase B signaling GO:0043491 10.16 PTEN KDR FGF2
9 stem cell proliferation GO:0072089 10.16 KDR FGF2 CD34
10 positive regulation of blood vessel endothelial cell migration GO:0043536 10.14 VEGFA KDR FGF2
11 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.13 VEGFA TEK PTEN MAP2K1 KDR FLT4
12 sprouting angiogenesis GO:0002040 10.12 FLT4 TEK VEGFA
13 negative regulation of endothelial cell apoptotic process GO:2000352 10.11 KDR KRIT1 TEK
14 cell motility GO:0048870 10.11 PTEN MAP2K1 CD34
15 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 10.11 VEGFA TEK KDR FGF2
16 cellular response to vascular endothelial growth factor stimulus GO:0035924 10.1 VEGFA KDR FLT4
17 positive regulation of MAPK cascade GO:0043410 10.1 FGF2 FLT4 KDR MAP2K1 TEK VEGFA
18 positive regulation of protein phosphorylation GO:0001934 10.1 FGF2 FLT4 KDR KRAS PECAM1 TEK
19 vascular endothelial growth factor receptor signaling pathway GO:0048010 10.09 VEGFA KDR FLT4
20 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 10.07 VEGFA KDR FGF2
21 positive regulation of focal adhesion assembly GO:0051894 10.06 VEGFA TEK KDR
22 endothelial cell proliferation GO:0001935 10.05 TEK FGF2 CD34
23 cell migration involved in sprouting angiogenesis GO:0002042 10.02 VEGFA KDR FGF2
24 vascular endothelial growth factor signaling pathway GO:0038084 10 VEGFA KDR FLT4
25 paracrine signaling GO:0038001 9.98 FGF2 CD34
26 lymphangiogenesis GO:0001946 9.97 PROX1 PDPN FLT4
27 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.96 VEGFA KDR
28 vascular endothelial growth factor receptor-2 signaling pathway GO:0036324 9.96 VEGFA KDR
29 glomerular endothelium development GO:0072011 9.95 PECAM1 CD34
30 blood vessel endothelial cell differentiation GO:0060837 9.93 PROX1 KDR
31 vascular wound healing GO:0061042 9.93 VEGFA KDR CD34
32 lymph vessel morphogenesis GO:0036303 9.91 PKD1 VEGFA
33 endothelium development GO:0003158 9.91 KRIT1 KDR CD34
34 lymphatic endothelial cell fate commitment GO:0060838 9.9 PDPN PROX1
35 lung development GO:0030324 9.9 VEGFA PROX1 PDPN NKX2-1 KDR FGF2
36 lymph vessel development GO:0001945 9.88 PROX1 KDR FLT4
37 regulation of axon regeneration GO:0048679 9.85 MAP2K1 PTEN
38 positive regulation of epithelial tube formation GO:1905278 9.83 VEGFA FGF2
39 positive regulation of phosphorylation GO:0042327 9.79 VEGFA KDR FLT4
40 positive regulation of endothelial cell proliferation GO:0001938 9.73 FGF2 FLT4 KDR PROX1 TEK VEGFA
41 positive regulation of endothelial cell migration GO:0010595 9.4 VEGFA TEK PROX1 KDR FLT4 FGF2

Molecular functions related to Hemangioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.73 TEK KDR FLT4
2 vascular endothelial growth factor receptor activity GO:0005021 9.46 KDR FLT4
3 chemokine binding GO:0019956 9.26 PDPN FGF2
4 protein tyrosine kinase activity GO:0004713 9.17 TEK MAP2K1 KDR FLT4
Sources

Sources for Hemangioma

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....